Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 13/20 | 0.73 |
| ▸ | HDAC8 | Q9BY41 | 10/20 | 0.73 |
| ▸ | HDAC6 | Q9UBN7 | 10/20 | 0.73 |
| ▸ | HDAC2 | Q92769 | 9/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 8/20 | 0.55 |
| ▸ | HDAC4 | P56524 | 7/20 | 0.55 |
| ▸ | HDAC7 | Q8WUI4 | 6/20 | 0.55 |
| ▸ | HDAC10 | Q969S8 | 6/20 | 0.55 |
| ▸ | HDAC11 | Q96DB2 | 6/20 | 0.55 |
| ▸ | HDAC9 | Q9UKV0 | 6/20 | 0.55 |
| ▸ | HDAC5 | Q9UQL6 | 6/20 | 0.55 |
| ▸ | MMP2 | P08253 | 1/20 | 0.53 |
| ▸ | MMP13 | P45452 | 1/20 | 0.53 |
| ▸ | APP | P05067 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6513450 | 1.00 | HDAC1 (0.73) | HDAC1HDAC8HDAC6HDAC2HDAC3 | |
| SCHEMBL5046073 | 0.84 | HDAC8 (1.00) | HDAC1HDAC8HDAC6HDAC2HDAC3 | |
| SCHEMBL5046075 | 0.84 | HDAC8 (1.00) | HDAC1HDAC8HDAC6HDAC2HDAC3 | |
| SCHEMBL13836663 | 0.83 | MMP2 (0.61) | HDAC1HDAC8HDAC6MMP2MMP13 | |
| SCHEMBL8767799 | 0.83 | MMP2 (0.61) | HDAC1HDAC8HDAC6MMP2MMP13 | |
| SCHEMBL13836664 | 0.83 | MMP2 (0.61) | HDAC1HDAC8HDAC6MMP2MMP13 | |
| SCHEMBL5566574 | 0.83 | HDAC8 (0.76) | HDAC1HDAC8HDAC6HDAC2HDAC3 | |
| SCHEMBL5566575 | 0.83 | HDAC8 (0.76) | HDAC1HDAC8HDAC6HDAC2HDAC3 | |
| SCHEMBL8769622 | 0.80 | POLB (0.60) | HDAC1HDAC8HDAC6MMP2MMP13 | |
| SCHEMBL13836049 | 0.80 | POLB (0.60) | HDAC1HDAC8HDAC6MMP2MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005066151-A2 | HISTONE DEACETYLASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2005-07-21 | — | — | WO | claimed |
| US-20050137234-A1 | Histone deacetylase inhibitors | SYRRX, INC. | 2005-06-23 | — | — | US | claimed |
| WO-2005066151-A2 | HISTONE DEACETYLASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2005-07-21 | — | — | WO | disclosed |
| US-20050137234-A1 | Histone deacetylase inhibitors | SYRRX, INC. | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137234-A1 | Histone deacetylase inhibitors | HDAC1, HDAC5, HDAC11 | HDAC1 1/4885HDAC8 7/4885HDAC6 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.